Certara (NASDAQ:CERT) Issues FY 2025 Earnings Guidance

Certara (NASDAQ:CERT) issued an update on its FY 2025 earnings guidance on Wednesday morning. The company provided EPS guidance of 0.420-0.460 for the period, compared to the consensus EPS estimate of 0.500. The company issued revenue guidance of $415.0 million-$425.0 million, compared to the consensus revenue estimate of $422.4 million.

Analysts Set New Price Targets

CERT has been the topic of a number of research analyst reports. Robert W. Baird decreased their price objective on shares of Certara from $18.00 to $13.00 and set a “neutral” rating on the stock in a report on Tuesday, November 5th. Barclays decreased their price target on shares of Certara from $14.00 to $12.00 and set an “equal weight” rating on the stock in a research note on Thursday, November 7th. Six equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $15.92.

Certara Trading Down 0.4 %

Shares of CERT traded down $0.05 on Wednesday, reaching $12.33. 1,212,151 shares of the company’s stock were exchanged, compared to its average volume of 1,273,763. The business has a 50 day moving average price of $12.36 and a two-hundred day moving average price of $11.63. The company has a current ratio of 2.86, a quick ratio of 2.86 and a debt-to-equity ratio of 0.28. The stock has a market capitalization of $1.98 billion, a P/E ratio of -61.65, a price-to-earnings-growth ratio of 9.29 and a beta of 1.57. Certara has a 12 month low of $9.41 and a 12 month high of $19.87.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.